Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide.

Albertí J, Martinet A, Sentellas S, Salvà M.

Drug Metab Dispos. 2010 Jul;38(7):1202-10. doi: 10.1124/dmd.109.031724. Epub 2010 Mar 23.

2.

Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites.

Sentellas S, Ramos I, Albertí J, Salvà M, Antón F, Miralpeix M, Beleta J, Gavaldà A.

Eur J Pharm Sci. 2010 Mar 18;39(5):283-90. doi: 10.1016/j.ejps.2010.01.004. Epub 2010 Jan 20. Review.

PMID:
20093184
3.

In vitro liver metabolism of aclidinium bromide in preclinical animal species and humans: identification of the human enzymes involved in its oxidative metabolism.

Albertí JJ, Sentellas S, Salvà M.

Biochem Pharmacol. 2011 Mar 15;81(6):761-76. doi: 10.1016/j.bcp.2010.12.013. Epub 2010 Dec 22.

PMID:
21184745
4.

Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide).

Prat M, Fernández D, Buil MA, Crespo MI, Casals G, Ferrer M, Tort L, Castro J, Monleón JM, Gavaldà A, Miralpeix M, Ramos I, Doménech T, Vilella D, Antón F, Huerta JM, Espinosa S, López M, Sentellas S, González M, Albertí J, Segarra V, Cárdenas A, Beleta J, Ryder H.

J Med Chem. 2009 Aug 27;52(16):5076-92. doi: 10.1021/jm900132z.

PMID:
19653626
5.

Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants.

Jansat JM, Lamarca R, de Miquel G, Schrödter A, Miletzki B, Gurniak M.

J Clin Pharmacol. 2009 Oct;49(10):1239-46. doi: 10.1177/0091270009336353. Epub 2009 Jul 10.

PMID:
19592595
6.

An update on the efficacy and safety of aclidinium bromide in patients with COPD.

Alagha K, Bourdin A, Tummino C, Chanez P.

Ther Adv Respir Dis. 2011 Feb;5(1):19-28. doi: 10.1177/1753465810381546. Epub 2010 Sep 30. Review. Erratum in: Ther Adv Respir Dis. 2011 Apr;5(2):151.

PMID:
20884687
7.

Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects.

Jansat JM, Lamarca R, Garcia Gil E, Ferrer P.

Int J Clin Pharmacol Ther. 2009 Jul;47(7):460-8.

PMID:
19640353
8.

Mass balance and metabolism of aclidinium bromide following intravenous administration of [¹⁴C]-aclidinium bromide in healthy subjects.

Ortiz S, Flach S, Ho J, Li F, Caracta CF, Gil EG, Jansat JM.

Biopharm Drug Dispos. 2012 Jan;33(1):39-45. doi: 10.1002/bdd.1773. Epub 2012 Feb 27.

PMID:
22275272
9.

Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD.

Cazzola M.

Curr Opin Investig Drugs. 2009 May;10(5):482-90. Review.

PMID:
19431081
10.

Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.

Gavaldà A, Miralpeix M, Ramos I, Otal R, Carreño C, Viñals M, Doménech T, Carcasona C, Reyes B, Vilella D, Gras J, Cortijo J, Morcillo E, Llenas J, Ryder H, Beleta J.

J Pharmacol Exp Ther. 2009 Nov;331(2):740-51. doi: 10.1124/jpet.109.151639. Epub 2009 Aug 26.

11.

Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants.

Ortiz S, Flach S, Caracta C, Gil EG, Jansat JM.

J Clin Pharmacol. 2012 Jun;52(6):819-27. doi: 10.1177/0091270011406281. Epub 2011 May 31.

PMID:
21628603
12.

Identification of rat and human cytochrome p450 isoforms and a rat serum esterase that metabolize the pyrethroid insecticides deltamethrin and esfenvalerate.

Godin SJ, Crow JA, Scollon EJ, Hughes MF, DeVito MJ, Ross MK.

Drug Metab Dispos. 2007 Sep;35(9):1664-71. Epub 2007 Jun 18.

13.

In vitro stability and metabolism of O2', O3', O5'-tri-acetyl-N6-(3-hydroxylaniline) adenosine in rat, dog and human plasma: chemical hydrolysis and role of plasma esterases.

Liu Y, He J, Abliz Z, Zhu H.

Xenobiotica. 2011 Jul;41(7):549-60. doi: 10.3109/00498254.2011.573016. Epub 2011 Apr 13.

PMID:
21486191
14.

Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease.

de la Motte S, Beier J, Schmid K, Pascual S, Jansat JM, Gil EG.

Int J Clin Pharmacol Ther. 2012 Jun;50(6):403-12. doi: 10.5414/CP201628.

PMID:
22541745
15.

Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial.

Schmid K, Pascual S, Gil EG, Ortiz S, Jansat JM.

Clin Ther. 2010 Sep;32(10):1798-812. doi: 10.1016/j.clinthera.2010.09.002.

PMID:
21194604
16.

Aclidinium bromide, a novel long-acting muscarinic antagonist for COPD with improved preclinical renal and urinary safety profile.

Gavaldà A, Gras J, Llupià J, Aubets J, Beleta J, Llenas J.

Life Sci. 2012 Feb 13;90(7-8):301-5. doi: 10.1016/j.lfs.2011.12.002. Epub 2011 Dec 22.

PMID:
22213116
17.

Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma.

Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen EG, Masson P, Lockridge O.

Biochem Pharmacol. 2005 Nov 25;70(11):1673-84. Epub 2005 Oct 6.

PMID:
16213467
18.

Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects.

Lasseter KC, Aubets J, Chuecos F, Gil EG.

J Clin Pharmacol. 2011 Jun;51(6):923-32. doi: 10.1177/0091270010374471. Epub 2010 Oct 19.

PMID:
20959525
19.

Species differences in hydrolysis of isocarbacyclin methyl ester (TEI-9090) by blood esterases.

Minagawa T, Kohno Y, Suwa T, Tsuji A.

Biochem Pharmacol. 1995 May 17;49(10):1361-5.

PMID:
7763277

Supplemental Content

Support Center